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igh-Dose Statins
rior to Percutaneous
oronary Intervention
Paradigm Shift to
nfluence Clinical Outcomes in the
ardiac Catheterization Laboratory*
otirios Tsimikas, MD
a Jolla, California
eriprocedural myocardial infarction (MI), generally de-
ned by consensus panels as creatine kinase-myocardial
soenzyme (CK-MB) elevation 3 the upper limit of
ormal (ULN), occurs in 5% to 15% of patients. It has been
emonstrated that elevation of CK-MB post-percutaneous
oronary intervention (PCI) is associated with increased
ong-term mortality, with a graded increase in risk accord-
ng to the extent of elevation (1). Periprocedural MI is
outinely used as an end point in clinical trials and increas-
ngly as a quality performance metric (2). These factors have
rought increasing focus on finding new methodologies to
educe periprocedural MI.
See page 2157
The major etiologies of periprocedural MI include dis-
ection, compromise of side branches due to plaque shifting,
hrombosis, distal embolization, and no-reflow phenome-
on. However, despite optimal management directed to-
ard mechanical and thrombotic complications, the rate of
eriprocedural MI is still too high, and therapies directed to
therosclerotic and inflammatory processes in the vessel wall
ay provide additional benefit (3).
In that regard, in this issue of the Journal, Briguori et al.
4) report the results of the Naples II (Novel Approaches for
reventing or Limiting Events II) open-label study, which
andomized 668 statin-naive patients (10% of the popu-
ation undergoing PCI from 2005 to 2008) undergoing PCI
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Vascular Medicine Program, University of California San Diego, La
olla, California. Dr. Tsimikas is on the Speakers’ Bureau of Merck, has receivedd
nvestigator-initiated grants from Pfizer, Novartis, and GlaxoSmithKline, and has
atent and patent applications for antibodies to oxidized LDL.o 80 mg of atorvastatin the day prior to PCI versus no
tatin therapy. Patients were typical of subjects with stable
ngina presenting for PCI with modestly elevated low-
ensity lipoprotein cholesterol (LDL-C) levels (124 mg/dl),
dvanced disease, and relatively complex procedures. A
ignificant reduction in the primary end point, CK-MB
3 ULN, was present in the atorvastatin group compared
ith the control group (9.5% vs. 15.8%). The benefit was
ot due to an unusually higher number of complications in
he control group, and likely not related to lowering plasma
DL-C levels which do not significantly decrease in 24 h.
As a result of iatrogenic plaque rupture during PCI,
esides the risk of mechanical complications, many vasoac-
ive and bioactive substances are released downstream into
he microcirculation, leading to vasoconstriction, endothe-
ial dysfunction, myocardial ischemia, and necrosis. These
nclude cholesterol clefts, thrombus, apoptotic bodies, mi-
roparticles derived from platelets and inflammatory cells,
xidized lipids (5,6), endothelin, angiotensin II, and other
actors (7). In initial statin trials of primary and secondary
revention, restenosis, or acute coronary syndromes (ACS),
he dosing of statin therapy was not linked to performance
f PCI, and these studies did not evaluate periprocedural
I. Although it cannot be answered from this study, one
as to speculate that the benefit of high-dose statins,
articularly those that could accumulate deep within the
laque, is mediated by rapid and direct effects due to
nti-inflammatory, antioxidative, antithrombotic, nitric
xide–sparing, immune-modulatory, and plaque-stabilizing
ffects on the vessel wall. These so-called pleiotropic prop-
rties of statins unrelated to changes in LDL-C have been
emonstrated in in vitro studies and in animal models,
ncluding showing that intravenous dosing of statins acutely
educes inflammation in a manner comparable to indometh-
cin (8). Removing or quenching the effects of these
ubstances locally and downstream of the plaque would
resumably result in lower ischemic events. In support of
his concept, reduction in C-reactive protein and adhesion
olecules has been demonstrated following PCI in subjects
re-treated with high-dose statins (9–12). However, al-
hough chronic pleiotropic properties cannot be easily ex-
mined in humans independent of statins’ lipid-lowering
ffects until more specific agents or molecular imaging
echniques are developed, acute pleiotropic effects in hu-
ans may be easier to evaluate because LDL-C would not
ignificantly change. Additional mechanistic studies should
e performed to understand the acute effects of statins on
ascular biology.
This study extends previous data in this field by demon-
trating that even a single high dose of a potent statin given
day prior to PCI results in a 40% reduction in periproce-
ural MI. The 6 studies in Table 1 provide strong evidence
hat high doses of potent statins lead to reduction of
eriprocedural MI. The ARMYDA (Atorvastatin for Re-
uction of MYocardial Damage during Angioplasty study)
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December 1, 2009:2164–6 Statins and PCInvestigators (9–11,13), initially in stable angina patients,
hen in patients with ACS, and finally in patients already on
tatins, uniformly demonstrated an improvement in 30-day
ajor adverse cardiac event (MACE) rates, which were
rimarily driven by a reduced rate of periprocedural MI.
urthermore, Yun et al. (14) recently showed in an open-
abel study that a single 40-mg dose of rosuvastatin resulted
n similarly improved MACE at 30 days.
Of course, it is well established that statin therapy should
e given to all patients with cardiovascular disease and in
articular those undergoing PCI. Therefore, one may won-
er why there is increasing emphasis on optimizing the
osage and type of statin in the periprocedural period. First,
lthough somewhat controversial, significant elevations of
K-MB are increasingly seen by interventional cardiolo-
ists, clinical trialists, regulatory bodies, and local and
ational quality performance committees as an adverse event
hat can be minimized. Second, a sizable minority of
ubjects are entering the cardiac catheterization laboratory
ithout statin therapy, even those with stable angina, as
oted in Naples II. Furthermore, subjects with ACS are
ow routinely catheterized within 24 h of admission and are
ften not on statins prior to admission or on presentation to
he cardiac catheterization laboratory. For example, in the
tudy of Yun et al. (14) and ARMYDA-ACS (10), 72% and
2% of patients, respectively, presented to the hospital
ithout prior statin therapy. Third, CK-MB is increasingly
sed as a metric of PCI quality, which can either reflect well
r poorly on the performing operators and hospitals. This
as significant implications on a variety of levels, from local
nd national prestige, patient referrals, training programs,
nd perhaps to reimbursement in the future. Interestingly,
ata from the American College of Cardiology National
ardiovascular Database CathPCI Registry (ACC-NCDR)
2), reflecting 231,395 patients and 463 hospitals, demon-
trates that the majority of U.S. hospitals are not routinely
easuring CK-MB following elective PCI. In fact, 10%
f hospitals routinely measured CK-MB in all patients
ndergoing elective PCI, and hospitals with less frequent
easurements had higher rates of periprocedural MI when
nzymes were measured, suggesting a significant underesti-
ation of the true incidence when levels are not measured
outinely. A level playing field in post-PCI measurement
ould be a welcome addition in defining the true incidence
f periprocedural MI in clinical practice.
It is to be emphasized that the major benefit of pre-PCI
tatin therapy is a reduction in periprocedural MI, and no
tudy thus far was powered to assess long-term, hard end
oints. Although the prognostic significance of very high
levations (5 ULN) of CK-MB has been demonstrated
15), it has not been determined whether modest elevations,
hich are often clinically silent, are directly related to the
ndex event or instead, identify patients with a particularly
igh-risk substrate. A sophisticated analysis of the 7,773
atients undergoing PCI from the ACUITY (Acute Cath-eterization and Urgent Intervention Triage Strategy) trialSt
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Statins and PCI December 1, 2009:2164–616) demonstrated that periprocedural MI occurs in 6.0% of
atients and spontaneous MI in 2.6% over a 1-year
ollow-up period. In unadjusted analyses evaluating 1-year
ortality, spontaneous MI (16.0%), and periprocedural MI
6.0%) had higher mortality compared with patients without
I (2.6%). However, after adjusting for clinical and proce-
ural characteristics, periprocedural MI was no longer
ssociated with increased mortality. Patients with peripro-
edural MI represent subjects with more risk factors and
ore extensive disease and complex plaque morphology.
onetheless, the imperative to reduce periprocedural MI is
trong, as it represents a patient at higher risk of future
ortality.
Armed with this knowledge, how should clinicians treat
atients potentially undergoing PCI? All patients should be
reated with a high dose of a potent statin as outpatients,
hich should be continued until the performance of PCI, or
s soon as possible on arrival at the hospital. In patients
reviously on statin therapy, it is not unreasonable to
onsider upstream use of high-dose, potent statins by
eloading at least 12 h prior to PCI. Whether doses of
tatins substantially higher than standard lipid-lowering
oses will result in even more benefit is an intriguing
uestion that can be addressed in future clinical trials. Based
n the current data, a rationale for further testing of higher
anti-inflammatory” doses in well-designed studies is
resent. Overall, these data have begun to generate a
aradigm shift so that high-dose, potent statins should no
onger be viewed for patients with ACS or as a discharge
rescription, but instead should be given similar priority as
spirin and clopidogrel prior to patients undergoing PCI. In
he final analysis, with validation of these data with larger
utcomes studies, all interested parties will benefit from this
xtension of the remarkable therapeutic efficacy of statins.
eprint requests and correspondence: Dr. Sotirios Tsimikas,
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